Takeda Collaborates with Engitix to Target Fibrotic Liver Diseases

 Takeda Collaborates with Engitix to Target Fibrotic Liver Diseases

Takeda Collaborates with Engitix to Target Fibrotic Liver Diseases

Shots:

  • Engitix to receive up front with additional payments based on the confirmation and functional validation of selected targets and is eligible to receive $500M as preclinical, development, regulatory and commercial milestones along with royalties on sales of therapies
  • Takeda to get the exclusive rights to develop and commercialize the candidate emerges from the collaboration. The companies will validate the targets and preclinical development of therapeutics in liver fibrosis
  • The agreement will focus on developing novel therapies for advanced fibrotic liver diseases, including NASH. The collaboration integrates Engitix’s ECM platform with Takeda’s expertise in gastroenterology R&D and commercialization

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Ali Miller RD

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post